Daratumumab with bortezomib and dexamethasone for relapsed or refractory multiple myeloma – second line
NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Project page URL
Myeloma is a type of cancer that affects blood cells which are made in the bone marrow. In patients with myeloma, the bone marrow is stopped from making enough normal healthy blood cells. Multiple myeloma affects multiple parts of the body and common affected areas include the spine, skull, rib cage, pelvis, and the bones of the arms, legs, shoulders, and hips. There is no cure for multiple myeloma; there are drug treatments that help control the disease but in most patients with multiple myeloma, the disease returns and so the patient needs to be treated again with different drugs. Daratumumab is a new drug for the treatment of multiple myeloma which is delivered straight into the blood. Some studies have suggested daratumumab (given with two treatments that are already commonly used) may be helpful for people whose first treatment has failed and whose disease has spread. If daratumumab is licensed for use in the UK, it could be a new treatment option for patients with multiple myeloma that could improve survival and quality of life when current treatments have not worked.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/daratumumab-with-bortezomib-and-dexamethasone-for-relapsed-or-refractory-multiple-myeloma-second-line/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Dexamethasone; Multiple Myeloma

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000422

Date abstract record published